<\/span><\/strong><\/h4>\n<\/span><\/strong><\/h4>\n<\/span><\/strong><\/p>\n<\/span><\/strong><\/p>\nConf. Dr. Gyula L\u00e1szl\u00f3 Fekete<\/span><\/strong>
Universitatea de Medicin\u0103 \u0219i Farmacie T\u00e2rgu-Mure\u0219, Rom\u00e2nia<\/span><\/strong><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″ locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.0.11″]<\/p>\n
Vasculita leucocitoclastic\u0103 cutanat\u0103 asociat\u0103 tratamentului cu erlotinib, prezentare de caz \u0219i revizuirea literaturii<\/span>
Autor: Fekete Gyula L\u00e1szl\u00f3, Fekete L\u00e1szl\u00f3<\/span><\/p>\nErlotinibul este o terapie anticancer folosit pentru tratarea cancerului pulmonar pozitiv la receptorul factorului de cre\u0219tere epidermal (EGFR) \u00een stadiu avansat, precum \u0219i pentru alte malignit\u0103\u021bi. Cel mai frecvent efect secundar cutanat al erlotinibului este bine documentat; cu toate acestea, num\u0103rul de prezent\u0103ri de cazuri privind vasculita leucocitoclastic\u0103 cutanat\u0103 (CLCV) este limitat. Prezent\u0103m un caz, o femeie de 58 de ani, cu greutatea de 60 kg, care suferea de adenocarcinom pulmonar \u0219i de metastaze cerebrale tratate cu monoterapie cu erlotinib \u00een doz\u0103 de 150 mg \/ zi, care prezint\u0103 o vasculit\u0103 leucocitoclastic\u0103 cutanat\u0103 dup\u0103 8 luni de la ini\u021bierea tratamentului. Administrarea medicamentului a fost \u00eentrerupt \u0219i ini\u0163iat tratament cu prednisolon pe cale oral\u0103 la o doz\u0103 de 1 mg \/ kg greutate corporal\u0103, timp de dou\u0103 s\u0103pt\u0103m\u00e2ni, sc\u0103z\u00e2nd doza cu 5 mg, la fiecare 3 zile. Tratamentul a fost combinat cu terapie steroidic\u0103 local\u0103 \u0219i antibiotic\u0103, utilizat\u0103 o dat\u0103 pe zi. Leziunile au fost disp\u0103rut \u00een decurs de 7 s\u0103pt\u0103m\u00e2ni f\u0103r\u0103 recuren\u021b\u0103. Tratamentul cu Erlotinib a fost reluat dup\u0103 14 zile de la cu o doz\u0103 mai mic\u0103 de 100 mg pe zi conform protocoalelor din literatura de specialitate. Leziunile cutanate nu au mai reap\u0103rut. Din p\u0103cate, evolu\u021bia a fost nefavorabil\u0103, pacientul a murit la 3 luni dup\u0103 vindecarea vasculitei, datorit\u0103 complica\u021biilor noilor metastaze care au ap\u0103rut. Aceasta fapt poate indica ineficien\u021ba Erlotinibului. Debutul \u00eent\u00e2rziat de 240 de zile de vasculit\u0103 \u0219i presupusa ineficien\u021b\u0103 a medicamentului, duc la specula\u021bia c\u0103 apari\u021bia vasculitei cutanate ar putea fi un marker clinic agravant al r\u0103spunsului tumoral. Cele nou\u0103 cazuri pe care le-am g\u0103sit \u00een literatura de specialitate exclud orice interpretare semnificativ\u0103 a datelor referitoare la vasculita cutanat\u0103 indus\u0103 de Erlotinib. Sunt necesare investiga\u021bii suplimentare pentru evaluarea vasculitei cutanate induse de Erlotinib.<\/p>\n
Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment, case report and review of the literature
Author: Fekete Gyula L\u00e1szl\u00f3, Fekete L\u00e1szl\u00f3<\/span><\/span><\/p>\nErlotinib is a targeted anticancer therapy used for treating epidermal growth factor receptor (EGFR) mutation positive lung cancer in advanced stage as well as for other malignancies. The most common cutaneous side effect of erlotinib, are well documented; however the number of reports regarding cutaneous leukocytoclastic vasculitis (CLCV) are limited. We report a case, a 58 years-old, 60 kg weight, non-smoking woman suffering of lung adenocarcinoma and brain metastases treated with erlotinib monotherapy with 150 mg\/day dose who presents a cutaneous leukocytoclastic vasculitis after 8 month of initiating the treatment. The administration of the drug was discontinued and oral prednisolone treatment was introduced at 1 mg\/kg body weight dose for two weeks, decreasing the dose with 5 mg, at every 3 days. The treatment was combined with topical potent steroid and antibiotic therapy used once, daily. The lesions cleared within 7 weeks without recurrence. The treatment with Erlotinib was restarted after 14 days with a lower dose of 100 mg\/day. The skin lesions have not occurred anymore. Unfortunately the evolution was unfavorable, our patient died at 3 months after healing the vasculitis, due to the complications of new metastases that occurred. This may indicate the inefficiency of Erlotinib. The late onset of 240 days of the vasculitis and the presumed inefficiency of the drug lead to the speculation that the appearance of cutaneous vasculitis could be a worsening clinical marker of the tumor response. This limited number of cases precludes any meaningful interpretation of data about the Erlotinib induced cutaneous vasculitis. Further investigations are needed to assess cutaneous vasculitis.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2020\/wp-content\/uploads\/2020\/02\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2020<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@primaderma.ro\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”3.19.4″ title_font=”||||||||”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2020<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n
![\"\"](\"https:\/\/pdi.ro\/2020\/wp-content\/uploads\/2020\/02\/eventer_logo_150px.png\")
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,7232,7231″ fullwidth=”on” _builder_version=”4.0.11″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Conf. Dr. Gyula L\u00e1szl\u00f3 Fekete Universitatea de Medicin\u0103 \u0219i Farmacie T\u00e2rgu-Mure\u0219, Rom\u00e2niaVasculita leucocitoclastic\u0103 cutanat\u0103 asociat\u0103 tratamentului cu erlotinib, prezentare de caz \u0219i revizuirea literaturii Autor: Fekete Gyula L\u00e1szl\u00f3, Fekete L\u00e1szl\u00f3 Erlotinibul este o terapie anticancer folosit pentru tratarea cancerului pulmonar pozitiv la receptorul factorului de cre\u0219tere epidermal (EGFR) \u00een stadiu avansat, precum \u0219i pentru alte […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-7521","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/pages\/7521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/comments?post=7521"}],"version-history":[{"count":4,"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/pages\/7521\/revisions"}],"predecessor-version":[{"id":8167,"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/pages\/7521\/revisions\/8167"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/media?parent=7521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/span><\/strong><\/p>\n <\/span><\/strong><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″ locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.0.11″]<\/p>\n Vasculita leucocitoclastic\u0103 cutanat\u0103 asociat\u0103 tratamentului cu erlotinib, prezentare de caz \u0219i revizuirea literaturii<\/span> Erlotinibul este o terapie anticancer folosit pentru tratarea cancerului pulmonar pozitiv la receptorul factorului de cre\u0219tere epidermal (EGFR) \u00een stadiu avansat, precum \u0219i pentru alte malignit\u0103\u021bi. Cel mai frecvent efect secundar cutanat al erlotinibului este bine documentat; cu toate acestea, num\u0103rul de prezent\u0103ri de cazuri privind vasculita leucocitoclastic\u0103 cutanat\u0103 (CLCV) este limitat. Prezent\u0103m un caz, o femeie de 58 de ani, cu greutatea de 60 kg, care suferea de adenocarcinom pulmonar \u0219i de metastaze cerebrale tratate cu monoterapie cu erlotinib \u00een doz\u0103 de 150 mg \/ zi, care prezint\u0103 o vasculit\u0103 leucocitoclastic\u0103 cutanat\u0103 dup\u0103 8 luni de la ini\u021bierea tratamentului. Administrarea medicamentului a fost \u00eentrerupt \u0219i ini\u0163iat tratament cu prednisolon pe cale oral\u0103 la o doz\u0103 de 1 mg \/ kg greutate corporal\u0103, timp de dou\u0103 s\u0103pt\u0103m\u00e2ni, sc\u0103z\u00e2nd doza cu 5 mg, la fiecare 3 zile. Tratamentul a fost combinat cu terapie steroidic\u0103 local\u0103 \u0219i antibiotic\u0103, utilizat\u0103 o dat\u0103 pe zi. Leziunile au fost disp\u0103rut \u00een decurs de 7 s\u0103pt\u0103m\u00e2ni f\u0103r\u0103 recuren\u021b\u0103. Tratamentul cu Erlotinib a fost reluat dup\u0103 14 zile de la cu o doz\u0103 mai mic\u0103 de 100 mg pe zi conform protocoalelor din literatura de specialitate. Leziunile cutanate nu au mai reap\u0103rut. Din p\u0103cate, evolu\u021bia a fost nefavorabil\u0103, pacientul a murit la 3 luni dup\u0103 vindecarea vasculitei, datorit\u0103 complica\u021biilor noilor metastaze care au ap\u0103rut. Aceasta fapt poate indica ineficien\u021ba Erlotinibului. Debutul \u00eent\u00e2rziat de 240 de zile de vasculit\u0103 \u0219i presupusa ineficien\u021b\u0103 a medicamentului, duc la specula\u021bia c\u0103 apari\u021bia vasculitei cutanate ar putea fi un marker clinic agravant al r\u0103spunsului tumoral. Cele nou\u0103 cazuri pe care le-am g\u0103sit \u00een literatura de specialitate exclud orice interpretare semnificativ\u0103 a datelor referitoare la vasculita cutanat\u0103 indus\u0103 de Erlotinib. Sunt necesare investiga\u021bii suplimentare pentru evaluarea vasculitei cutanate induse de Erlotinib.<\/p>\n Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment, case report and review of the literature Erlotinib is a targeted anticancer therapy used for treating epidermal growth factor receptor (EGFR) mutation positive lung cancer in advanced stage as well as for other malignancies. The most common cutaneous side effect of erlotinib, are well documented; however the number of reports regarding cutaneous leukocytoclastic vasculitis (CLCV) are limited. We report a case, a 58 years-old, 60 kg weight, non-smoking woman suffering of lung adenocarcinoma and brain metastases treated with erlotinib monotherapy with 150 mg\/day dose who presents a cutaneous leukocytoclastic vasculitis after 8 month of initiating the treatment. The administration of the drug was discontinued and oral prednisolone treatment was introduced at 1 mg\/kg body weight dose for two weeks, decreasing the dose with 5 mg, at every 3 days. The treatment was combined with topical potent steroid and antibiotic therapy used once, daily. The lesions cleared within 7 weeks without recurrence. The treatment with Erlotinib was restarted after 14 days with a lower dose of 100 mg\/day. The skin lesions have not occurred anymore. Unfortunately the evolution was unfavorable, our patient died at 3 months after healing the vasculitis, due to the complications of new metastases that occurred. This may indicate the inefficiency of Erlotinib. The late onset of 240 days of the vasculitis and the presumed inefficiency of the drug lead to the speculation that the appearance of cutaneous vasculitis could be a worsening clinical marker of the tumor response. This limited number of cases precludes any meaningful interpretation of data about the Erlotinib induced cutaneous vasculitis. Further investigations are needed to assess cutaneous vasculitis.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2020\/wp-content\/uploads\/2020\/02\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n Contacteaz\u0103 operatorul PDI 2020<\/p>\n [\/et_pb_text][et_pb_contact_form email=”contact@primaderma.ro\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”3.19.4″ title_font=”||||||||”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n Operatorul PDI 2020<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n <\/span><\/p>\n <\/span><\/p>\n Adresa: Str. A. Panu nr. 13, Iasi<\/span> [\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n Parteneri Media<\/p>\n [\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,7232,7231″ fullwidth=”on” _builder_version=”4.0.11″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Conf. Dr. Gyula L\u00e1szl\u00f3 Fekete Universitatea de Medicin\u0103 \u0219i Farmacie T\u00e2rgu-Mure\u0219, Rom\u00e2niaVasculita leucocitoclastic\u0103 cutanat\u0103 asociat\u0103 tratamentului cu erlotinib, prezentare de caz \u0219i revizuirea literaturii Autor: Fekete Gyula L\u00e1szl\u00f3, Fekete L\u00e1szl\u00f3 Erlotinibul este o terapie anticancer folosit pentru tratarea cancerului pulmonar pozitiv la receptorul factorului de cre\u0219tere epidermal (EGFR) \u00een stadiu avansat, precum \u0219i pentru alte […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-7521","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/pages\/7521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/comments?post=7521"}],"version-history":[{"count":4,"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/pages\/7521\/revisions"}],"predecessor-version":[{"id":8167,"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/pages\/7521\/revisions\/8167"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/media?parent=7521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Conf. Dr. Gyula L\u00e1szl\u00f3 Fekete<\/span><\/strong>
Universitatea de Medicin\u0103 \u0219i Farmacie T\u00e2rgu-Mure\u0219, Rom\u00e2nia<\/span><\/strong><\/h4>\n
Autor: Fekete Gyula L\u00e1szl\u00f3, Fekete L\u00e1szl\u00f3<\/span><\/p>\n
Author: Fekete Gyula L\u00e1szl\u00f3, Fekete L\u00e1szl\u00f3<\/span><\/span><\/p>\n<\/span><\/p>\n
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n